Genitourinary drugs market seen reaching $38.29 billion by 2035

Market Research Future projects the global genitourinary drugs market will rise from $32.84 billion in 2026 to $38.29 billion by 2035. Growth is being driven by aging populations, faster bladder-cancer drug approvals, and wider use of telemedicine and precision therapies.

Why it matters: - The genitourinary drugs market is moving from a generic-heavy segment toward precision biologics, oncology drugs and digital prescribing models. - The shift matters because aging populations and higher diagnosis rates are expanding demand for treatments for prostate disorders, overactive bladder, chronic kidney disease, erectile dysfunction and urinary tract infections. - Market Research Future expects that mix to support steady revenue growth through 2035, even with a modest 1.72% CAGR.

What happened: - Market Research Future said the global genitourinary drugs market will grow from $32.84 billion in 2026 to $38.29 billion by 2035. - The firm estimated the market at $32.28 billion in 2025. - The forecast covers the 2026-2035 period and implies a 1.72% compound annual growth rate. - The report was released Aug. 17, 2026.

The details: - Aging is a core demand driver, with WHO projections showing the global population over 65 will top 1.6 billion by 2050. - Urinary incontinence affects an estimated 423 million adults worldwide, while treatment rates in primary care remain below 40%. - Japan's 2024 nationwide geriatric screening mandate now includes verified bladder-function exams. - India's Ayushman Bharat scheme added urology-specific diagnostic packages in 2024, covering an additional 120 million beneficiaries for benign prostatic hyperplasia and kidney stone treatment. - The FDA's Real-Time Oncology Review program has cut median approval timelines for bladder-cancer therapies from 10.5 months to 6.2 months. - The EMA's PRIME designation has moved three overactive-bladder candidates to accelerated assessment since 2023. - Antibody-drug conjugates targeting Nectin-4 and Trop-2 are becoming a major pipeline category in bladder cancer. - Enfortumab vedotin generated more than $1.8 billion in global sales in 2024. - At least four additional ADC candidates are in Phase II/III trials for metastatic urothelial carcinoma. - Telehealth has become a larger access channel for urology care, with post-pandemic utilization for urological consultations stabilizing at about 28% of initial visits in the U.S. through 2024. - Ro and Hims expanded combined annual revenues past $1.2 billion in 2024, reflecting stronger digital demand for erectile dysfunction prescribing. - The FDA approved seven novel genitourinary entities in 2024. - The market's top five companies hold an estimated 38%-44% combined revenue share.

Between the lines: - The forecast suggests the market's biggest upside is coming less from broad volume growth and more from therapy upgrades, faster access and specialty-care expansion. - Oncology is becoming the clearest value pool, especially as bladder-cancer therapies move through faster review pathways and biologic drugs gain share. - Telemedicine and direct-to-patient prescribing are widening the market for erectile dysfunction and urinary tract infection drugs, which could keep prescription volumes rising even in slower-growth categories. - The report also points to cost pressure and competition from generics, but says expedited regulation and biosimilar openings may still expand the treatable patient pool.

What's next: - Market Research Future expects AI-enabled drug discovery to shorten lead-optimization timelines and improve trial efficiency by the early 2030s. - The report says immuno-oncology crossover could become the single largest growth vector, with the addressable value of those products possibly exceeding $8 billion by 2035. - Gene and cell therapies for overactive bladder are advancing in U.S. Phase II trials and could create a premium niche by 2030 if results hold. - Leuprolide and goserelin biosimilars entering Europe and Asia-Pacific between 2026 and 2029 could lower treatment costs and expand access. - Digital therapeutics and companion diagnostics are likely to become more tightly linked with prescription workflows and reimbursement. - The market is projected to reach $38.29 billion by 2035.

The bottom line: - Genitourinary drugs are entering a slower but more specialized growth phase, powered by aging demographics, bladder-cancer innovation and digital access rather than by broad market expansion.